Trials / Recruiting
RecruitingNCT06816108
A Study of ONO-7428 in Participants With Unresectable Advanced or Recurrent Solid Tumors
A Phase I, Open-label, Dose Escalation Study to Evaluate the Tolerability and Safety of ONO-7428 in Participants With Unresectable Advanced or Recurrent Solid Tumors
- Status
- Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 60 (estimated)
- Sponsor
- Ono Pharmaceutical Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study is to evaluate the tolerability and safety of ONO-7428 in participants with unresectable advanced or recurrent solid tumors.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ONO-7428 | Specified dose on specified days |
Timeline
- Start date
- 2025-04-21
- Primary completion
- 2029-07-01
- Completion
- 2029-07-01
- First posted
- 2025-02-10
- Last updated
- 2026-01-12
Locations
15 sites across 1 country: Japan
Source: ClinicalTrials.gov record NCT06816108. Inclusion in this directory is not an endorsement.